Do you want to read an article? Please log in or register.
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Multiple Sclerosis
Related content
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, Ariño H, González-Álvarez V, Felipe-Rucián A, Jesús Martínez-González M, Cantarín-Extremera V, Concepción Miranda-Herrero M, Monge-Galindo L, Tomás-Vila M, Miravet E, Málaga I, Arrambide G, Auger C, Tintoré M, Montalban X, Vanderver A, Graus F, Saiz A, Dalmau J, Spanish Pediatric anti-MOG Study Group.
doi: 10.1016/S1474-4422(19)30488-0.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Comparison of the response to rituximab between MOG- and AQP4-antibody diseases
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Ann Neurol.
Durozard P, Rico A, Boutiere C, Maarouf A, Lacroix R, Cointe S, Fritz S, Brunet C, Pelletier J, Marignier R, Audoin B
doi: 10.1002/ana.25648.
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
Aging and Cognitive FunctionsAlzheimer’s DiseaseDementia
Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.
JAMA Neurol.
Dean DC 3rd, Hurley SA, Kecskemeti SR, O'Grady JP, Canda C, Davenport-Sis NJ, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Johnson SC, Alexander AL, Bendlin BB
doi: 10.1001/jamaneurol.
Multiple Sclerosis
Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course.
Ther Adv Neurol Disord.
Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME
doi: 10.1177/1756286419878340.
Multiple Sclerosis
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
Mult Scler
Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS
doi: 10.1177/13524585211035740
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Anxiety and Depression
Defining Treatment Response and Remission in Youth Anxiety: A Signal Detection Analysis With the Multidimensional Anxiety Scale for Children
J Am Acad Child Adolesc Psychiatry.
Palitz SA, Caporino NE, McGuire JF, Piacentini J, Albano AM, Birmaher B, Walkup JT, Compton SN, Ginsburg GS, Kendall PC
doi: 10.1016/j.jaac.2018.03.013.
RECOMMENDED
Multiple Sclerosis
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Neurology.
Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L
doi: 10.1212/WNL.